FeesSafety
Pluang+

Bitcoin struggles near $82K with uncertain year-end rally amid key Fed decisions.

Market News
23 Oct 2026
Coinpaper
View Source
Neutral
Bitcoin struggles near $82K with uncertain year-end rally amid key Fed decisions.

Bitcoin is trading around $81,700 after failing to break above $85,000, remaining 35% below its all-time high. The cryptocurrency faces resistance near $84,000-$85,000 and $87,000-$87,500, with $90,000 as a critical target for a strong recovery. Upcoming Federal Reserve interest rate decisions in late October and December could impact Bitcoin's price by influencing investor sentiment and borrowing costs. Analysts outline three scenarios for Bitcoin's year-end: a bullish breakout above $90,000 towards $100,000, a neutral range-bound movement between $80,000-$90,000, or a bearish drop below $80,000 potentially down to $75,000-$77,500.

Bitcoin price outlook provides context for cryptocurrency market activity on Pluang as of Oct 23, 2026 20:03 WIB. Among 50 major cryptocurrencies, 29 rose and 20 fell today. Bitcoin Cash gained 3.46% to Rp5,129,306 with a strong buy interest at 73%, contrasting with Cosmos which rose 3.33% to Rp31,900 but saw 90% sell activity. Filecoin declined 2.87% to Rp17,718 despite 76% buy orders, showing varied investor behavior across assets.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
43 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App